Giving Drugs a Second Chance: Overcoming Regulatory and Financial Hurdles in Repurposing Approved Drugs As Cancer Therapeutics
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Giving Drugs a Second Chance: Overcoming Regulatory and Financial Hurdles in Repurposing Approved Drugs As Cancer Therapeutics
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 7, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2017-11-14
DOI
10.3389/fonc.2017.00273
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Scientific advice — is drug repurposing missing a trick?
- (2017) Pan Pantziarka Nature Reviews Clinical Oncology
- Cancer Drugs: An International Comparison of Postlicensing Price Inflation
- (2017) Philip Savage et al. Journal of Oncology Practice
- In silico prediction and in vitro and in vivo validation of acaricide fluazuron as a potential inhibitor of FGFR3 and a candidate anticancer drug for bladder carcinoma
- (2016) Kunbin Ke et al. Chemical Biology & Drug Design
- Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma
- (2016) K. Satoh et al. CLINICAL CANCER RESEARCH
- Busting the billion-dollar myth: how to slash the cost of drug development
- (2016) Amy Maxmen NATURE
- In silico and in vitro drug screening identifies new therapeutic approaches for Ewing sarcoma
- (2016) Ziyan Y. Pessetto et al. Oncotarget
- Opportunities and Challenges for Drug Development: Public–Private Partnerships, Adaptive Designs and Big Data
- (2016) Oktay Yildirim et al. Frontiers in Pharmacology
- Health Plan Utilization and Costs of Specialty Drugs Within 4 Chronic Conditions
- (2016) Patrick P. Gleason et al. JOURNAL OF MANAGED CARE PHARMACY
- Computational and Practical Aspects of Drug Repositioning
- (2015) Tudor I. Oprea et al. ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES
- A survey of current trends in computational drug repositioning
- (2015) Jiao Li et al. BRIEFINGS IN BIOINFORMATICS
- Adapalene inhibits the activity of cyclin-dependent kinase 2 in colorectal carcinoma
- (2015) XI-NAN SHI et al. Molecular Medicine Reports
- Drug repurposing in oncology—patient and health systems opportunities
- (2015) Francesco Bertolini et al. Nature Reviews Clinical Oncology
- In Silico Identification and In Vitro and In Vivo Validation of Anti-Psychotic Drug Fluspirilene as a Potential CDK2 Inhibitor and a Candidate Anti-Cancer Drug
- (2015) Xi-Nan Shi et al. PLoS One
- Cyclin-Dependent Kinase-2 as a Target for Cancer Therapy: Progress in the Development of CDK2 Inhibitors as Anti-Cancer Agents
- (2014) Tahir Chohan et al. CURRENT MEDICINAL CHEMISTRY
- In silico identification of potential targets and drugs for non-small cell lung cancer
- (2014) Chien-Hung Huang et al. IET Systems Biology
- Drug Repurposing Identifies a Synergistic Combination Therapy with Imatinib Mesylate for Gastrointestinal Stromal Tumor
- (2014) Z. Y. Pessetto et al. MOLECULAR CANCER THERAPEUTICS
- CDK1 and CDK2 activity is a strong predictor of renal cell carcinoma recurrence
- (2014) Fumiya Hongo et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Identification of repurposed small molecule drugs for chordoma therapy
- (2013) Menghang Xia et al. CANCER BIOLOGY & THERAPY
- Using computational strategies to predict potential drugs for nasopharyngeal carcinoma
- (2013) Ming-Ying Lan et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Trifluoperazine, an Antipsychotic Agent, Inhibits Cancer Stem Cell Growth and Overcomes Drug Resistance of Lung Cancer
- (2012) Chi-Tai Yeh et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Applications of Connectivity Map in drug discovery and development
- (2012) Xiaoyan A. Qu et al. DRUG DISCOVERY TODAY
- Diagnosing the decline in pharmaceutical R&D efficiency
- (2012) Jack W. Scannell et al. NATURE REVIEWS DRUG DISCOVERY
- An Integrated Bioinformatics Approach Identifies Elevated Cyclin E2 Expression and E2F Activity as Distinct Features of Tamoxifen Resistant Breast Tumors
- (2011) Lei Huang et al. PLoS One
- Gene Expression-Based Chemical Genomics Identifies Potential Therapeutic Drugs in Hepatocellular Carcinoma
- (2011) Ming-Huang Chen et al. PLoS One
- From NPC Therapeutic Target Identification to Potential Treatment Strategy
- (2010) M.-Y. Lan et al. MOLECULAR CANCER THERAPEUTICS
- Lessons from 60 years of pharmaceutical innovation
- (2009) Bernard Munos NATURE REVIEWS DRUG DISCOVERY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now